Listeriolysin from Listeria and Their Effecting on AHNP

Abstract

Conventional anti-cancer therapy involves the use of chemical chemotherapeutics and radiation and are often non-specific in action. A major shortcoming in current treatment has been the development of drug resistance and inability to penetrate tumor cells. Alternative antitumor medicines with higher specificity and efficacy have therefore been explored. There is Significant interest in exploring the use of microbes as potential anticancer agents. We will introduce bacterial anti-cancer therapy with a focus on the various mechanisms involved in tumor targeting and suppression in this review. The bacteriotherapy in the design of novel treatments, approaches in combination with conventional cancer treatment may be effective in cancer therapies. We're focusing on the progress that has been made in the treatment of bacterial cancer. Patients in cancer treatment are attracted to tumor targeting peptides. These peptides are widely studied, delivering anticancer agents to tumor sites. In this study, we produced a new form of recombinant listeriolysin O (LLO) with genetically fused Anti HER2/neu peptide (AHNP) sequence adding to its C terminal end. The aim of the study was to engineer this pore forming toxin to make it much more specific to tumor cells. The results show that the LLO C terminal should not be changed, and it appears for the purpose of engineering and adding peptide modules, the N terminal of the toxin should be preferred. development of the small molecule that these constrained peptides provide drugs, but also provide insight into the atomic features of protein-protein interactions.